Alder biopharmaceuticals inc (ALDR)
CashFlow / TTM
Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-317,354

-327,332

-296,429

-270,697

-269,342

-275,582

-288,879

-283,413

-258,982

-223,219

-156,254

-133,528

-125,391

-104,180

-85,470

-66,247

-10,604

-350

8,908

11,975

-22,580

-20,326

-20,613

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Equity in net loss of unconsolidated entity

-

-

-222

-402

-586

-716

-643

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

2,029

2,299

2,567

2,908

3,123

3,055

3,001

2,898

2,655

2,186

1,674

1,194

871

791

751

745

731

708

701

754

817

882

935

0

0

0

Loss on retirement of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

30,210

25,762

25,420

25,348

24,766

23,264

22,498

20,820

18,510

16,120

13,957

11,874

10,181

8,246

6,139

4,616

3,168

2,012

1,250

900

670

564

575

0

0

0

Accretion of discount on convertible notes

12,271

11,949

10,596

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash change in fair value of derivative liability

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash charges, net

3,394

3,266

3,142

2,698

1,927

951

167

-342

-642

-566

-407

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-113

-81

-57

-91

-203

-17

-76

-65

188

0

0

0

Prepaid expenses and other assets

3,361

-3,493

-3,574

-10,947

-13,580

-12,546

-37,366

-13,680

4,506

3,281

31,374

14,542

2,967

5,120

9,744

9,579

9,527

10,086

5,196

4,993

722

-2,478

-1,053

0

0

0

Accounts payable

-8,010

2,349

1,273

-6,721

-4,206

-7,420

-2,395

17,032

12,474

10,908

5,488

-2,038

5,224

7,432

2,816

6,049

-317

511

-312

562

2,029

-255

303

0

0

0

Accrued liabilities

28,106

30,782

3,414

-3,185

-516

2,397

366

5,130

6,531

4,206

7,843

3,896

3,255

441

4,273

4,157

2,515

2,406

835

-760

-773

424

142

0

0

0

Deferred rent

-

-

-3

46

62

37

14

334

287

361

373

-16

-33

-110

-128

-117

30

181

276

284

133

-25

-129

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-54,324

-52,494

-18,437

-18,414

-18,253

0

0

0

Net cash used in operating activities

-258,198

-251,331

-250,850

-233,526

-226,889

-239,313

-226,617

-222,623

-221,925

-193,805

-159,687

-134,822

-110,766

-92,465

-81,233

-66,607

-58,969

-54,152

-47,657

-43,755

-38,784

-34,564

-36,132

0

0

0

Investing activities
Purchases of investments

99,786

171,614

522,795

584,513

764,237

692,409

305,540

275,667

138,592

187,639

165,871

139,155

221,492

179,445

185,629

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

193,919

201,919

321,629

365,858

367,846

443,811

341,819

264,660

261,488

152,523

104,765

79,925

21,445

24,360

19,335

0

0

0

-

-

-

-

5,620

0

0

0

Proceeds from sales of investments

-

-

83,184

0

0

0

-

-

-

-

-

-

-

-

250

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

3,898

3,227

3,136

1,391

801

1,413

2,050

3,053

5,192

6,537

6,619

6,063

3,530

1,779

1,223

963

983

1,004

649

486

413

164

193

0

0

0

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

90,235

27,078

-121,118

-136,862

-313,857

-166,676

34,380

-13,909

117,704

-41,653

-67,720

-65,288

-203,572

-156,859

-167,267

-165,147

-11,383

-21,364

-9,734

-9,797

-8,149

5,330

5,546

0

0

0

Financing activities
Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-36

0

0

0

-

-

-

0

-

-

-

0

Proceeds from issuance of 2025 convertible senior notes, net of offering costs

-

-

277,656

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of offering costs

-

-

97,710

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of offering costs

0

0

-

-

-

-

-

-

-

-

-

-

-

-

406,634

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,536

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

0

-

-

-

0

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

0

-

0

0

0

Net cash provided by financing activities

161,928

162,288

377,937

377,464

538,711

538,232

162,917

163,234

1,974

137,136

137,110

136,703

136,368

217,423

408,206

408,254

408,123

272,532

80,982

80,425

80,579

-690

48

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

21

32

40

26

-9

-46

-62

-44

-23

16

30

22

12

0

0

0

Net increase in cash, cash equivalents and restricted cash

-6,035

-61,965

5,969

7,076

-2,035

132,243

-29,320

-73,298

-102,247

-98,322

-90,276

-63,375

-177,930

-31,875

159,697

176,454

337,709

196,972

23,568

26,889

33,676

-29,902

-30,526

0

0

0

Supplemental disclosures:
Cash paid for interest

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs included in accounts payable and accrued liabilities

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued liabilities

206

375

209

418

153

-71

8

209

-552

416

503

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-